PKA phosphorylation of the small heat shock protein Hsp20 enhances its cardioprotective effects

Helen V. Edwards¹*, John D. Scott² and George S. Baillie¹

1 Centre for Molecular Pharmacology, College of Medical, Veterinary and Life Sciences, University of Glasgow, University Avenue, Glasgow, G12 8QQ, U.K. Tel: +44 141 330 1662, and 2 Howard Hughes Medical Institute, Department of Pharmacology, University of Washington School of Medicine, PO Box 357750, Seattle, WA 98195, USA

*To whom correspondence should be addressed (email: h.edwards.1@research.gla.ac.uk)

Key words
Small heat shock protein
Cardioprotection
Hsp20
Phosphorylation
PKA
Phosphodiesterase type 4 (PDE4)

Abbreviations used
Hsp, heat shock protein; sHsp, small heat shock protein; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; PKA, protein kinase A; PKG, protein kinase G; PDE, phosphodiesterase; AKAP, A-kinase anchoring protein; I/R, ischaemia/reperfusion; TG, transgenic; wt, wildtype; ASK-1, apoptosis signal-regulating kinase 1; JNK, c-Jun N terminal kinase; PKC, protein kinase C; PKD, protein kinase D; HDAC, histone deacetylase; Gs, stimulatory G protein; AC, adenylyl cyclase.

Abstract
The small heat shock protein Hsp20 has been shown to protect against a number of pathophysiological cardiac processes, including hypertrophy and apoptosis. Following β-adrenergic stimulation and local increases in cAMP, Hsp20 is phosphorylated on Serine 16 by protein kinase A. This covalent modification is required for many of its cardioprotective effects. Both Hsp20 expression levels and its phosphorylation on Serine 16 are increased in ischaemic myocardium. Transgenic mouse models with cardiac-specific overexpression of Hsp20 that are subject to ischaemia/reperfusion show smaller myocardial infarcts, and improved recovery of contractile performance during the reperfusion phase, compared with wildtype mice. This has been attributed to Hsp20’s ability to protect against cardiomyocyte necrosis and apoptosis. Phospho-mimics of Hsp20 (Ser16 to Asp mutants) confer improved protection from β-agonist induced apoptosis in the
heart, whereas phospho-null mutants (Ser16 to Ala) provide no protection. Naturally occurring mutants of Hsp20 at position 20 (P20L substitution) are associated with markedly reduced Hsp20 phosphorylation at Serine 16, and this lack of phosphorylation correlates with abrogation of Hsp20’s cardioprotective effects. Therefore phosphorylation of Hsp20 at Serine 16 by PKA is vital for the cardioprotective actions of this small heat shock protein. Selective targeting of signalling elements that can enhance this modification represents an exciting new therapeutic avenue for the prevention and treatment of myocardial remodelling and ischaemic injury.

Introduction

Heat shock proteins (Hsps) are a diverse group of molecular chaperones that are upregulated in response to cellular stress. Originally described in *Drosophila melanogaster* as a group of proteins whose expression was increased at elevated temperatures [1], Hsps have been extensively characterised, and a variety of cellular triggers for their induction have now been identified, including ischaemia/reperfusion (I/R) [2], oxidative stress [3] and glucose deprivation [4]. The chaperone activities of Hsps include prevention of protein misfolding, refolding of denatured proteins, and their targeting for proteolytic degradation [5]. Heat shock proteins may be broadly classified according to their molecular weights as either high molecular weight (e.g. Hsp90, Hsp70) or low molecular weight/small heat shock proteins (sHsps). The sHsps, which include Hsp20, are less frequently induced by heat stress, and several family members, such as Hsp27 and alphaB-crystallin, are known to be abundant in cardiac and skeletal muscle, where they increase in response to stress to protect against muscle ischaemia [5, 6].

Many heat shock proteins are now known to play essential protective roles in the cardiovascular system. This mini-review focuses on the protective actions of the small heat shock protein Hsp20 in the heart, with particular emphasis on cardiac hypertrophy and ischaemia/reperfusion injury, and how phosphorylation of Hsp20 by protein kinase A enhances these cardioprotective effects.

Small heat shock proteins

sHsps are a diverse group of proteins with different sub-cellular localisation and tissue distribution [7]. To date, 10 sHsp isoforms have been identified, and these are formally classified as HspB1-B10 [8]. Hsp20, also known as HspB6, is expressed at high levels in cardiac, skeletal and vascular smooth muscle, where it represents up to 1% of total protein [7, 9]. sHsps range from 12–43 kDa, and are characterised by a stretch of amino acids in their C termini known as the alpha-crystallin domain, which facilitates their chaperone activities [8] (see Figure 1). In addition to the alpha-crystallin domain, Hsp20 also possesses an N terminal domain which is involved in inhibiting platelet aggregation, and a region similar to the minimal inhibitory region of troponin I, which is thought to be involved in actin binding (Figure 1) [6]. Hsp20 has long been a focus of interest in the field of cardiovascular research, as it is the only sHsp to contain a cAMP/cGMP-dependent protein kinase (PKA/PKG) consensus phosphorylation sequence, of the form R13-R-A-S16, within its N terminus [7, 10]. Thus, Hsp20 may be regulated by the β-adrenergic/cAMP/PKA signalling pathway, which is known to be chronically activated in heart failure. PKG phosphorylation of Hsp20, in response to nitric oxide stimulation of guanylyl cyclases, and generation of cyclic GMP, has been shown to modulate smooth muscle relaxation, and is discussed in detail elsewhere [10-12].
**β-adrenergic signalling and Hsp20 phosphorylation**

In cardiac cells, stress results in a rise in circulating catecholamines and β-adrenergic stimulation triggers increased intracellular generation of the second messenger cyclic AMP. The concomitant activation of PKA permits the phosphorylation of key downstream targets involved in excitation-contraction coupling. These include the ryanodine receptor and phospholamban, which regulate calcium handling at the sarcoplasmic reticulum, and myofilament proteins directly involved in contraction, such as troponin I and myosin-binding protein C. The net result is to increase the rate and efficiency of myocyte contraction, and improve cardiac output [13]. Initially, this acts to compensate for the provoking stress. However, upon chronic upregulation of cAMP synthesis, these effects become detrimental, leading to cardiomyocyte hypertrophy, apoptosis, and further deterioration in cardiac function. [14].

In cells, PKA activity is tightly regulated in amplitude, space and time by the compartmentalisation of cAMP [15]. A freely diffusible entity, cAMP can potentially flood the interior of the cell causing inappropriate phosphorylation and activation of downstream PKA targets. This situation is avoided by the opposing action of cyclic nucleotide phosphodiesterases (PDEs). Members of the PDE superfamily provide the only means of hydrolysing cAMP within the cell, and intracellular targeting of PDEs enables the creation of sub-cellular compartments with high levels of cAMP relative to the surrounding environment [16]. Thus, PDEs have the capacity to influence activation of PKA, and the phosphorylation status of PKA target proteins. Recently, we have shown that isoforms of the PDE4 family form a complex with Hsp20 [17]. Under basal conditions, this interaction maintains Hsp20 in a hypophosphorylated state. Upon prolonged β-adrenergic stimulation, as is seen in the failing heart, the pool of PDE4 tethered to Hsp20 becomes swamped, leading to a local increase in cAMP, PKA activation, and phosphorylation of Hsp20 on Serine 16 [17].

A further level of regulation is provided by A-kinase anchoring proteins (AKAPs). AKAPs are a diverse group of scaffold proteins that organise cellular signalling pathways by tethering PKA and other signalling enzymes to specific locations within the cell [18]. Previously, no AKAP had been identified for the pool of PKA that phosphorylates Hsp20; however Hsp20 has now been shown to interact with AKAP-Lbc, an anchoring protein that is enriched in cardiomyocytes (Edwards, H. V. and Baillie, G. S., unpublished data). This is an interesting observation, as AKAP-Lbc has been implicated in the development of cardiac hypertrophy (discussed further below) [19].

**Cardioprotective effects of Hsp20**

**Ischaemia-reperfusion injury and cardiomyocyte apoptosis**

One of the commonest causes of heart failure is myocardial ischaemia, with subsequent progression to infarction [20]. Even transient ischaemia can lead to myocardial necrosis and apoptosis. Myocardial reperfusion strategies aim to reduce morbidity and mortality by restoring tissue oxygenation, but may in fact result in further cellular damage, due to mitochondrial generation of reactive oxygen species. This phenomenon is known as ischaemia/reperfusion (I/R) injury [21]. It is now recognised that Hsp20 plays an important role in protecting against I/R injury. Major evidence in support of this role has come from the use of transgenic (TG) mouse models. TG mice with cardiac-specific overexpression of Hsp20 subject to I/R displayed a 6-fold reduction in myocardial infarct size, and improved recovery of contractile performance during reperfusion, compared with wildtype mice [22]. The molecular mechanisms underlying this dramatic reduction in infarct size
have been investigated by studies on isolated TG heart preparations. Hsp20-overexpressing TG hearts exhibited reduced release of LDH, consistent with reduced necrosis, and a significant reduction in DNA fragmentation and TUNEL staining, indicating attenuation of apoptosis. The observed effects on apoptosis may be explained by evidence that Hsp20 can interact with the pro-apoptotic protein Bax, thus preventing its translocation from the cytosol to mitochondria, and repression of caspase-3 activity [22].

Levels of phospho-S16 Hsp20 were more than doubled following 24 hours of reperfusion in the TG hearts, suggesting that this modification may be necessary to protect against I/R injury. Indeed, the importance of Hsp20 phosphorylation by PKA in mediating its cardioprotective effects has been comprehensively illustrated by studies employing Hsp20 phospho-site mutations. Here, Serine 16 is substituted for either non-phosphorylatable Alanine (S16A), or Aspartate (S16D) to mimic constitutive phosphorylation. Fan et al employed recombinant adenoviral transfer of wildtype (wt)-Hsp20, S16D-Hsp20 and S16A-Hsp20 into cultured adult cardiomyocytes. Ad-Hsp20-wt protected against β-agonist-induced apoptosis, as determined by a reduction in pyknotic nuclei, and this Hsp20 was shown to be significantly phosphorylated [23]. S16D overexpression provided even greater protection against apoptosis than the wildtype protein, whereas the S16A mutant conferred no such protection. Consistent with these observations, caspase-3 activity was reduced by 10% in wildtype-infected cells, 25% in S16D-treated cells, and was unaffected in S16A cells [23].

When S16A was substituted for overexpression of wt Hsp20 in the transgenic mouse, this led to impaired functional recovery of hearts ex vivo during I/R compared with non-transgenic hearts. S16A transgenic hearts also exhibited increased necrosis and apoptosis [2]. The increased cardioprotective abilities of phosphorylated Hsp20 may be in part associated with its ability to activate autophagy pathways. Autophagy, a physiological catabolic pathway enabling the cell to degrade and recycle damaged organelles, is known to be upregulated in myocardial ischaemia [24]. S16A transgenic hearts exhibited an impaired ability to activate autophagy post I/R, compared with wildtype, and pre-treatment of S16A hearts with rapamycin (an activator of autophagy pathways) improved their functional recovery in response to I/R injury [2].

The role of S16 phosphorylation of Hsp20 in cardioprotection is further exemplified by genetic screening studies performed in patients with dilated cardiomyopathy. Screening identified a C59T base substitution in the first exon of the Hsp20 gene in a subset of screened individuals both with and without heart disease. This single nucleotide polymorphism results in a proline to leucine change at position 20 (P20L), just downstream of the PKA site, and is associated with changes in secondary structure [25]. Adenoviral transfer of Hsp20-P20L into adult rat cardiomyocytes was associated with significantly diminished Ser16 phosphorylation following I/R, and complete abrogation of the anti-apoptotic effects of Hsp20 [25], again illustrating the fundamental importance of this modification. It is clear from the data presented above that modulation of Hsp20 Serine 16 phosphorylation represents a key therapeutic target in the treatment of ischaemic heart disease.

Cardiac hypertrophy

Serine 16 phosphorylation of Hsp20 has also been shown to protect against cardiac hypertrophy. Hypertrophy may be a beneficial physiological response, for example in the case of elite athletes, to improve cardiac output, or a pathological process that occurs secondary to pressure/volume overload associated with hypertension and valvular heart disease [5]. Hsp20 expression is increased in response to hypertrophic stimuli, such as chronic β-adrenergic stimulation [2, 23]. TG mice with cardiac-specific overexpression of Hsp20 and subject to chronic β-adrenergic stimulation with the synthetic agonist isoproterenol, are protected from the increases in heart weight/body weight ratio and cardiomyocyte size that are the hallmarks of cardiac hypertrophy [26]. In addition, TG hearts show reduced induction of the fetal gene response that accompanies hypertrophy. These effects
have been linked to suppression of ASK-1 (apoptosis signal-regulating kinase 1) signalling, with reduced activation of the downstream JNK(c-Jun N terminal kinase)/p38 signalling pathway [26].

The importance of phosphorylation of Hsp20 at Serine 16 in protection against cardiac hypertrophy has recently been highlighted by a study on phosphodiesterases. Members of the PDE4 family have been shown to form a complex with Hsp20, which maintains it in a dephosphorylated state until chronic β-adrenergic stimulation and a consequent sustained rise in the cAMP level saturates the PDE, allowing phosphorylation of Hsp20 [17]. Using peptide array technology and in vitro binding assays, the docking site for Hsp20 on PDE4 was mapped to the conserved catalytic region of the PDE. This sequence information was then used to design a cell-permeable disruptor peptide which specifically inhibited the interaction between Hsp20 and PDE4. Treatment of neonatal rat cardiomyocytes with this peptide disruptor led to highly phosphorylated endogenous Hsp20, and attenuation of β-agonist-induced hypertrophy, as determined by a reduction in cardiomyocyte size and measurement of fetal gene expression [17]. This study provides further direct evidence that alteration of the phosphorylation status of Hsp20, and not just the expression level of the protein, is required to fully realise its cardioprotective effects.

Recent unpublished data from our lab indicates an interaction between Hsp20 and the multipurpose scaffold protein, AKAP-Lbc, to facilitate its phosphorylation by PKA. In the heart, AKAP-Lbc anchors PKA and PKC to mediate activation of a third anchored kinase, PKD1 [19]. Interestingly, expression of AKAP-Lbc is increased in hypertrophic cardiomyocytes, and it has been proposed that this augments PKD1 activation, which favours phosphorylation and nuclear export of HDAC5, and the consequent depression of hypertrophic genes [19]. Taken together, these results suggest that induction of cardiac hypertrophy may involve a complex signalling interplay centring on AKAP-Lbc, where PKD activation favours a hypertrophic phenotype, and PKA activation, with subsequent phosphorylation of Hsp20, opposes these effects (see Figure 2). Further studies are required to understand how Hsp20 and the AKAP interact, and whether this interaction is deregulated in cardiac disease.

Conclusions

Heart failure, resulting from ischaemic heart disease and cardiomyopathy, presents an increasing financial and medical burden. Strategies which selectively modulate components of the β-adrenergic signalling pathway have long been of interest in the search for more effective treatments for heart failure [13]. Phosphorylation of Hsp20 at Serine 16 is significantly increased under ischaemic conditions in transgenic mice hearts [2]. The ratio of phospho-S16 to total Hsp20 has also been found to increase in failing human hearts compared with donor hearts [2]. Therefore, as a PKA effector with significant cardioprotective abilities, Hsp20 is of considerable interest as a potential therapeutic target.

Acknowledgements

We thank members of the Scott lab at the University of Washington, Seattle for helpful discussions regarding AKAP-Lbc.

Disclosures
None to declare.

Funding

G.S.B. is supported by grants from the Medical Research Council [U.K.; G0600765] and Fondation Leducq [06CVD02]. H.V.E. is supported by a BBSRC grant. JDS was supported in part by NIH grant HL088366.

References


Figure 1: Schematic of the domain structure of Hsp20. Hsp20 is a 160 amino acid protein. A 9 amino acid motif (WLRRASAPL) at its N terminus has been shown to inhibit thrombin-induced platelet aggregation [6]. This region encompasses a PKA/PKG consensus phosphorylation sequence, RRAS(16), which allows the function of the protein to be regulated by β-adrenergic signalling. The C terminal alpha-crystallin domain is common to all sHSPs, and aids in their chaperone activities [2]. In Hsp20, this domain also encompasses a region similar to the minimal inhibitory region of the thin filament-associated protein Troponin I (GFVAREFRRYRL), which may facilitate its interaction with actin [6]. Hsp20 has been shown to translocate to the myofilament under ischaemic conditions [27], and is able to bind actin [28], therefore it may also play a role in stabilising the cytoskeleton during ischaemic stress [29].
Figure 2: Proposed role of Hsp20 in protecting against β-agonist-induced hypertrophy. Following β-adrenergic stimulation, a local cAMP gradient is generated via the action of PDE4 isoforms directly associated with Hsp20. With sustained production of cAMP, the local PDE4 complement becomes saturated, leading to the activation of PKA, which may be scaffolded by AKAP-Lbc. PKA then phosphorylates Hsp20 on Serine 16, leading to induction of its cardioprotective actions [17]. Following α-adrenergic stimulation, PKC isoforms also scaffolded by AKAP-Lbc can phosphorylate anchored PKD. Combined PKA/PKC phosphorylation leads to the activation and translocation of PKD to the nucleus, where it contributes to the depression of transcription factors involved in the fetal gene response, a key mediator of the hypertrophic phenotype [19].